JLE

Epileptic Disorders

MENU

Major intra-familial variability in Unverricht-Lundborg disease Volume 24, issue 1, February 2022

  • [1] Gargouri-Berrechid A., Nasri A., Kacem I., Sidhom Y., Abdelkefi I., Hizem Y. Long-term evolution of EEG in Unverricht-Lundborg disease. Neurophysiol Clin. 2016;46:119-124. 2
  • [2] Berrechid A.G., Bendjebara M., Bouteiller D., Nasri A., Peuvion J.N., Marie Y. Juvenile myoclonic epilepsy phenotype in a family with Unverricht-Lundborg disease. Epileptic Disord. 2019;21:359-365. 4
  • [3] Kälviäinen R., Khyuppenen J., Koskenkorva P., Eriksson K., Vanninen R., Mervaala E. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia. 2008;49:549-556. 4
  • [4] Möller J.C., Hamer H.M., Oertel W.H., Rosenow F. Late-onset myoclonic epilepsy in Down's syndrome (LOMEDS). Seizure. 2002;11:303-305. Suppl. A
  • [5] Chew N.K., Mir P., Edwards M.J., Cordivari C., Martino D., Schneider S.A. The natural history of Unverricht-Lundborg disease: a report of eight genetically proven cases. Mov Disord. 2008;23:107-113. 1
  • [6] Oi Y., Kobayashi K., Hitomi T., Matsumoto R., Ikeda A., Takahashi R. Low-dose perampanel improved cortical myoclonus and basophobia in a patient with Unverricht-Lundborg disease: a case report. Rinsho Shinkeigaku. 2018;58:622-625. 10
  • [7] Könönen M., Danner N., Koskenkorva P., Kälviäinen R., Hyppönen J., Mervaala E. Reduced cortical activation in inferior frontal junction in Unverricht-Lundborg disease (EPM1) – A motor fMRI study. Epilepsy Res. 2015;111:78-84.
  • [8] de Carvalho M.R., Velasques B.B., Freire R.C., Cagy M., Marques J.B., Teixeira S. Frontal cortex absolute beta power measurement in panic disorder with agoraphobia patients. J Affect Disord. 2015;184:176-181.
  • [9] Gouider R., Ibrahim S., Fredj M., Gargouri A., Saïdi H., Ouezzani R. Unverricht-Lündborg disease: clinical and electrophysiologic study of 19 Maghreb families. Rev Neurol (Paris). 1998;154:503-507. 6-7
  • [10] Crespel A., Ferlazzo E., Franceschetti S., Genton P., Gouider R., Kälviäinen R. Unverricht-Lundborg disease. Epileptic Disord. 2016;18:28-37. S2
  • [11] Lalioti M.D., Scott H.S., Genton P., Grid D., Ouazzani R., M’Rabet A. A PCR amplification method reveals instability of the dodecamer repeat in progressive myoclonus epilepsy (EPM1) and no correlation between the size of the repeat and age at onset. Am J Hum Genet. 1998;62:842-847. 4
  • [12] Hyppönen J., Äikiä M., Joensuu T., Julkunen P., Danner N., Koskenkorva P. Refining the phenotype of Unverricht-Lundborg disease (EPM1): a population-wide Finnish study. Neurology. 2015;84:1529-1536. 15
  • [13] Canafoglia L., Ferlazzo E., Michelucci R., Striano P., Magaudda A., Gambardella A. Variable course of Unverricht-Lundborg disease: early prognostic factors. Neurology. 2017;89:1691-1697. 16
  • [14] Canafoglia L., Ciano C., Panzica F., Scaioli V., Zucca C., Agazzi P. Sensorimotor cortex excitability in Unverricht-Lundborg disease and Lafora body disease. Neurology. 2004;63:2309-2315. 12
  • [15] Danner N., Säisänen L., Määttä S., Julkunen P., Hukkanen T., Könönen M. Motor cortical plasticity is impaired in Unverricht-Lundborg disease. Mov Disord. 2011;26:2095-2100. 11
  • [16] Kälviäinen R., Genton P., Andermann E., Andermann F., Magaudda A., Frucht S.J. Brivaracetam in Unverricht-Lundborg disease (EPM1): results from two randomized, double-blind, placebo-controlled studies. Epilepsia. 2016;57:210-221. 2
  • [17] Khiari H.M., Franceschetti S., Jovic N., Mrabet A., Genton P. Death in Unverricht-Lundborg disease. Neurol Sci. 2009;30:315-318. 4
  • [18] Satishchandra P., Sinha S. Progressive myoclonic epilepsy. Neurol India. 2010;58:514-522. 4
  • [19] Koskenkorva P., Niskanen E., Hyppönen J., Könönen M., Mervaala E., Soininen H. Sensorimotor, visual, and auditory cortical atrophy in Unverricht-Lundborg disease mapped with cortical thickness analysis. AJNR Am J Neuroradiol. 2012;33:878-883. 5